Contact us
For General Inquiries Email: info@nirmidas.com
For Product Support Email: support@nirmidas.com
Researchers at Stanford have made a breakthrough that could ultimately allow doctors to peer inside your body without imaging machines like MRI or CT scanners. See the article on ABC 7 News.Researchers at Stanford have made a breakthrough that could ultimately allow doctors to peer inside your body without imaging machines like MRI or CT scanners. (KGO-TV )
STANFORD NEWSNirmidas Biotech Inc. has licensed a patent from Stanford University on biocompatible NIR-II dye that can be excited in the 600-900 nm range and fluoresces in the 900-1300 nm range. This NIR-II dye product (IR-E1100) has high quantum yield (~ 4 times higher than the Stanford dye and carbon nanotube based dyes), high biocompatibility, and can be renal excreted. This dye can be used for
MEDCITYNEWSStanford University spinout Nirmidas Biotech has raised $2 million in seed funding to commercialize its fluorescence technology that enhances 100-fold a researcher’s ability to detect disease biomarkers, said the company’s R&D director Joshua Robinson. It’s meant to pick up the subtle traces found in blood from early-stage cancer or hard-to-read autoimmune disorders – conditions tha
WALL STREET JOURNAL"Nirmidas Biotech Inc., a spin-out from Stanford University with technology that amplifies fluorescence in laboratory samples in a bid to better identify disease, has raised $2 million in seed funding to begin commercialization, the company said. The funding was led by an undisclosed Washington-based firm, joined by an undisclosed angel investor and the Stanford-StartX Fund, the
PRWEB"With pGOLD technology, afflictions such as cancer, auto-immune disorders, cardiovascular disease, and diabetes can be detected at earlier stages and with better accuracy by creating non-invasive, point-of-care testing. Early detection could significantly change the nature and cost of patient care."
NANOTECHWEB.ORGA plasmonic chip to diagnose type-1 diabetes? This is exactly what researchers at Stanford University have invented. The chip, capable of detecting biomarkers such as insulin-specific autoantibodies, might be used in hospitals and doctors surgeries as a quick and simple way to detect early-stage T1D.